In contrast, the relatively low tumor response of 10% with ibrutinib in these DLBCL PDX models is not consistent with clinical observations of ibrutinib in patients with wild type CD79B ABC-DLBCL (ORR 31%6), or when combined with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) in patients with GCB-DLBCL (ORR 90%34). The gene discussed is CD79B; the disease is neoplasm.